Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Cibinqo (abrocitinib by Year
Cibinqo (abrocitinib — atopic dermatitis) — International reported YoY (%) (%)
Pfizer Cibinqo (abrocitinib: 35.0% in FY2025, down 19.0 pts from a year earlier.
Latest, FY2025
35.0%
Period ended Dec 31, 2025
Change on a year earlier
-19.0 pts
54.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Cibinqo | 284 | 215 | 32% | 32% | 115 | 90 | 28% | 169 | 126 | 35% | 34%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cibinqo (abrocitinib — atopic dermatitis) — International reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.0% | -19.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 54.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Pfizer Cibinqo (abrocitinib (%), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/cibinqo-yoy-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.